Filing Details

Accession Number:
0001562180-24-006015
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-05 18:39:14
Reporting Period:
2024-08-01
Accepted Time:
2024-08-05 18:39:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590877 Regenxbio Inc. RGNX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1191229 N Argeris Karabelas C/O Regenxbio Inc.
9804 Medical Center Drive
Rockville MD 20850
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-01 10,000 $3.76 21,286 No 4 M Direct
Common Stock Acquisiton 2024-08-01 100 $12.74 21,386 No 4 M Direct
Common Stock Disposition 2024-08-01 9,600 $13.45 11,786 No 4 S Direct
Common Stock Disposition 2024-08-01 400 $14.59 11,386 No 4 S Direct
Common Stock Disposition 2024-08-01 100 $15.00 11,286 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2024-08-01 100 $0.00 100 $12.74
Common Stock Stock Options (Right to Buy) Disposition 2024-08-01 10,000 $0.00 10,000 $3.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,400 2026-06-01 No 4 M Direct
20,000 2025-05-19 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $13.20 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $14.44 to $14.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016.
  5. The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months.